Atrial fibrillation is under-recognized in chronic heart failure: Insights from a heart failure cohort treated with cardiac resynchronization therapy

Europace

Volumn 11, Issue 10, 2009, Pages 1295-1300

  Caldwell, Jane C ^a,b   Contractor, Hussain ^a   Petkar, Sanjiv ^a   Ali, Razwan ^a   Clarke, Bernard ^a   Garratt, Clifford J ^a,b   Neyses, Ludwig ^a,b   Mamas, Mamas A ^a,b  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Atrial fibrillation; CRT; Heart failure

Indexed keywords

AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CONTROLLED STUDY; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PACEMAKER; PRIORITY JOURNAL; PROGNOSIS; SINUS RHYTHM; THROMBOEMBOLISM;

AGED; ATRIAL FIBRILLATION; CARDIAC PACING, ARTIFICIAL; COHORT STUDIES; COMORBIDITY; FALSE NEGATIVE REACTIONS; FEMALE; GREAT BRITAIN; HEART FAILURE; HUMANS; INCIDENCE; MALE; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 70349488041     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eup201     Document Type: Article

References (31)

1. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, patho-physiology, and rationale for therapy. Am J Cardiol 2003;91:2-8.
2. Rivero-Ayerza M, Scholte op Reimer W, Lenzen M, Theuns DAMJ, Jordaens L, Komajda M et al. New-onset atrial fibrillation is an independent predictor of in-hospital mortality in hospitalized heart failure patients: results of the EuroHeart Failure Survey. Eur Heart J 2008;29:1618-1624
3. Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC et al. for the Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure survey programme-a survey on the quality of care among patients with heart failure in Europe: Part 1: patient characteristics and diagnosis. Eur Heart J 2003;24: 442-463 (Pubitemid 36286187)
4. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. J Am Coll Cardiol 1998;32:695-703.
5. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.
6. Carson PE, Johnson GR, Dunkman WB, Fletcher RD, Farrell L, Cohn JN. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT studies. The V-HeFT VA Cooperative Studies Group. Circulation 1993;87:VI102-10.
7. Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). Circulation 1998;98:2574-2579
8. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K et al. The Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 1999;341:857-865
9. Doval H, Nul D, Grancelli H, Perrone S, Bortman G, Curiel R, for grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Ran-domised trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994;344:493-498
10. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-1435
11. Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJV et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) Program. J Am Coll Cardiol 2006;47:1997-2004.
12. Savelieva I, Camm AJ. Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management. J Interv Card Electrophysiol 2000;4:369-382
13. Corell P, Gustafsson F, Schou M, Markenvard J, Nielsen T, Hildebrandt P. Prevalence and prognostic significance of atrial fibrillation in outpatients with heart failure due to left ventricular systolic dysfunction. Eur J Heart Fail 2007;9: 258-265
14. Dixen U, Wallevik L, Hansen MS, Haghfelt A, Aqraou KF, Abildstrom SZ et al. Prolonged signal-averaged P wave duration as a prognostic marker for morbidity and mortality in patients with congestive heart failure. Scand Cardiovasc J 2003;37: 193-198
15. Puglisi A, Gasparini M, Lunati M, Sassara M, Padeletti L, Landolina M et al. Persistent atrial fibrillation worsens heart rate variability, activity and heart rate, as shown by a continuous monitoring by implantable biventricular pacemakers in heart failure patients. J Cardiovasc Electrophysiol 2008;19:693-701.
16. Crijns HJGM, Tjeerdsma G, de Kam PJ, Boomsma F, Van Gelder IC, van den Berg MP et al. Prognostic value of the presence and development of atrial fibrilla-tion in patients with advanced chronic heart failure. Eur Heart J 2000;21:1238-1245
17. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003;107:2920-2925
18. Mathew J, Hunsberger S, Fleg J, Mc Sherry F, Williford W, Yusuf S. Incidence, predictive factors, and prognostic significance of supraventricular tachyarrhythmias in congestive heart failure. Chest 2000;118:914-922
19. Hoppe UC, Casares JM, Eiskjaer H, Hagemann A, Cleland JGF, Freemantle N et al. Effect of cardiac resynchronization on the incidence of atrial fibrillation in patients with severe heart failure. Circulation 2006;114:18-25.
20. Fung JW-H, Yu CM, Chan JY-S, Chan HC-K, Yip GW-K, Zhang Q et al. Effects of cardiac resynchronization therapy on incidence of atrial fibrillation in patients with poor left ventricular systolic function. Am J Cardiol 2005;96:728-731
21. Yannopoulos D, Lurie KG, Sakaguchi S, Milstein S, Ermis C, VanHeel L et al. Reduced atrial tachyarrhythmia susceptibility after upgrade of conventional implanted pulse generator to cardiac resynchronization therapy in patients with heart failure. J Am Coll Cardiol 2007;50:1246-1251
22. Mamas M, Contractor H, Fath-Ordoubadi F, Garratt C, Neyses L, Caldwell J. A meta-analysis of CRT in patients with heart failure and the development of atrial fibrillation. Eur J Heart Fail 2008;(Suppl. 7):176.
23. Pai RG, Varadarajan P. Prognostic significance of atrial fibrillation is a function of left ventricular ejection fraction. Clin Cardiol 2007;30:349-354
24. Ahmed A, Thornton P, Perry GJ, Allman RM, DeLong JF. Impact of atrial fibrilla-tion on mortality and readmission in older adults hospitalized with heart failure. Eur J Heart Fail 2004;6:421-426
25. Clark DM, Plumb VJ, Epstein AE, Kay GN. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol 1997;30:1039-1045
26. Pozzoli M, Cioffi G, Traversi E, Pinna GD, Cobelli F, Tavazzi L. Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm. J Am Coll Cardiol 1998;32:197-204.
27. Friberg L, Hammar N, Pettersson H, Rosenqvist M. Increased mortality in paroxysmal atrial fibrillation: report from the Stockholm Cohort-Study of Atrial Fibrillation (SCAF). Eur Heart J 2007;28:2346-2353
28. Nieuwlaat R, Dinh T, Olsson SB, Camm AJ, Capucci A, Tieleman RG et al. on behalf of the Euro Heart Survey Investigators. Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation? Eur Heart J 2008;29:915-922
29. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. J Am Coll Cardiol 2000;35:183-187
30. Hohnloser H, Capucci A, Fain E, Gold MR, Van Gelder IC, Healey J et al. ASympto-matic atrial fibrillation and Stroke Evaluation in pacemaker patients and the atrial fibrillation Reduction atrial pacing Trial (ASSERT). Am Heart J 2006;152:442-447
31. Glotzer TV, Daoud EG, Wyse DG, Singer DE, Holbrook R, Pruett K et al. Rationale and design of a prospective study of the clinical significance of atrial arrhythmias detected by implanted device diagnostics: the TRENDS study. J Interv Card Electrophysiol 2006;15:9-14.